In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on NuVasive (NASDAQ: NUVA), with a price target of $76. The company’s shares closed yesterday at $71.26, close to its 52-week high of $72.12.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 30.5% and a 76.6% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.
Currently, the analyst consensus on NuVasive is a Strong Buy with an average price target of $73.11, representing a 2.6% upside. In a report issued on September 17, Canaccord Genuity also reiterated a Buy rating on the stock with a $80 price target.
.
See today’s analyst top recommended stocks >>
NuVasive’s market cap is currently $3.66B and has a P/E ratio of 90.20. The company has a Price to Book ratio of 4.69.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.
